Skip to main content

Table 3 Clinicopathological characteristics of patients with sarcopenia and intramuscular fat deposition

From: “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”

VariableSarcopeniaIntramuscular fat deposition
Yes
(N = 31)
No
(N = 69)
P-valueYes
(N = 65)
No
(N = 35)
P-value
Age, mean ± SD57.64 ± 10.6553.85 ± 11.320.11856.83 ± 10.8351.68 ± 11.260.041
Gender male, N (%)23 (74.19)51 (73.91)0.97649 (75.38)25 (71.43)0.667
Body mass index (kg/m2), median (IQR)17.30 (16.11–19.85)20.32 (19.20–24.13)< 0.00119.82 (17.63–23.04)19.83 (17.85–23.12)0.903
Viral status, N (%) 0.415 0.166
 HBV21 (67.74)37 (53.62) 42 (64.62)16 (45.71) 
 HCV2 (6.45)6 (8.70)5 (7.69)3 (8.57)
 HBV + HCV0000
 None8 (25.81)26 (37.68)18 (27.69)16 (45.71)
Child–Pugh class, N (%)†‡ < 0.001 < 0.001
 A10 (32.26)50 (72.46) 29 (44.62)31 (88.57) 
 B15 (48.39)17 (24.64)29 (44.62)3 (8.57)
 C6 (19.35)2 (2.90)7 (10.77)1 (2.86)
AST (IU/L), median (IQR) 190.0 (85.0–262.5)94.0 (47.0–174.0)0.274138.0 (71.0–256.0)67.0 (36.0–132.5)0.031
ALT (IU/L), median (IQR)61.0 (27.5–82.5)40.0 (24.0–77.0)0.96546.0 (28.0–82.0)33.0 (21.5–69.0)0.833
Total Bilirubin (mg/dl), median (IQR)1.11 (0.68–2.25)0.92 (0.5–1.31)0.1321.16 (0.55–1.80)0.80 (0.47–1.09)0.093
Albumin (g/dl), median (IQR) ab3.06 (2.64–3.48)3.41 (2.99–3.91)0.0103.13 (2.68–3.60)3.55 (3.22–3.94)0.004
INR, median (IQR) ab1.19 (1.08–1.33)1.10 (0.99–1.25)0.0371.17 (1.07–1.32)1.05 (0.99–1.17)0.001
Platelet count (× 1000/μl), median (IQR)270.0 (194.0–297.25)276.0 (201.0–328.0)0.474270.0 (194.0–317.0)283.0 (220.5–321.0)0.292
CRP, mean (mg/L) ± SDb59.56 ± 7.1254.89 ± 6.550.82771.81 ± 7.5034.61 ± 4.670.049
Creatinine, mean (mg/dl) ± SD0.98 ± 0.530.88 ± 0.360.2510.94 ± 0,450.85 ± 0.350.309
Random blood glucose, mean (mg/dl) ± SD117.27 ± 39.35121.00 ± 37.970.661120.65 ± 42.29118.19 ± 29.210.768
Blood sodium, mean (mEq/L) ± SDab133.61 ± 5.19135.35 ± 5.070.131133.66 ± 4.72137.00 ± 5.240.002
Blood potassium, mean (mEq/L) ± SDa3.97 ± 1.473.21 ± 1.790.0353.56 ± 1.643.20 ± 1.880.334
BCLC stage, N (%)b 0.002 < 0.001
 A1 (3.22)6 (8.70) 1 (1.54)6 (17.14) 
 B3 (9.68)22 (31.88)9 (13.85)16 (45.71)
 C20 (64.52)39 (56.52)46 (70.77)13 (37.14)
 D7 (22.58)2 (2.90)9 (13.85)0
AFP level, N (%)b 0.416 0.001
  < 200 ng/ml13 (41.94)35 (50.72) 23 (35.38)25 (71.43) 
  ≥ 200 ng/ml18 (58.06)34 (49.28)42 (64.62)10 (28.57)
  1. SD Standard deviation, IQR Interquartile range, HCV Hepatitis C virus, HBV Hepatitis B virus, AST Aspartate aminotransferase, ALT Alanine transaminase, INR International normalised ratio, CRP C-reactive protein, BCLC Barcelona Clinic Liver Cancer, AFP Alpha-fetoprotein. aVariables that were significantly different between patients with and without sarcopenia. bVariables that were significantly different between IMF and non-IMF patients